What type of study is this?

This is a Systematic Review study.

September 10, 2025Open Access

Long-term Safety and Efficacy of Ixekizumab in Patients With Moderate to Severe Psoriasis – a Systematic Review of Randomised Controlled Trials

View Full Paper

Ask AI

Bookmark

Authors

Systematic review highlights ixekizumab's safety and efficacy in treating psoriasis, comparing outcomes to placebo.

Ixekizumab demonstrated superior efficacy in improving PASI scores compared to placebo, suggesting it is effective for psoriasis treatment.
Among 4705 participants in 6 trials, most adverse events reported were mild, indicating a favorable safety profile.
Systematic review followed PRISMA guidelines and included only randomised clinical trials, ensuring robust results.
Despite its efficacy, ixekizumab's usage remains relatively lower than conventional immunomodulatory agents in psoriasis management.

Shankar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 10, 2025Open Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review highlights ixekizumab's safety and efficacy in treating psoriasis, comparing outcomes to placebo.

Ixekizumab demonstrated superior efficacy in improving PASI scores compared to placebo, suggesting it is effective for psoriasis treatment.
Among 4705 participants in 6 trials, most adverse events reported were mild, indicating a favorable safety profile.
Systematic review followed PRISMA guidelines and included only randomised clinical trials, ensuring robust results.
Despite its efficacy, ixekizumab's usage remains relatively lower than conventional immunomodulatory agents in psoriasis management.

Shankar et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark